Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.

| Name |
|---|
Revenue Change |
Gross Change |
EBITDA Change |
EBIT Change |
Earnings Change |
Adlai Nortye Ltd is a clinical-stage company at the forefront of discovering and developing cancer therapies. The company is building a robust pipeline of drug candidates focused on two key areas where it believes it can make a difference...
Benzinga Rankings give you vital metrics on any stock – anytime.
You can purchase shares of Adlai Nortye (NASDAQ:ANL) through any online brokerage.
Other companies in Adlai Nortye’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Moderna Inc (NASDAQ:MRNA).
Adlai Nortye has a consensus price target of $30.80.
The stock price for Adlai Nortye (NASDAQ: ANL) is $11.02 last updated October 19, 2026 at 4:32 AM EDT.
There are no upcoming dividends for Adlai Nortye.
Adlai Nortye does not have any upcoming earnings scheduled.
There is no upcoming split for Adlai Nortye.
Adlai Nortye is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.